Takeda Pharmaceutical (TAK) OPEX Segregation (2016 - 2024)

KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Acquisitions Amortization Amortizatization of Intangibles Asset Writedowns and Impairment Capital Expenditures Cash from Financing Activities Cash from Investing Activities Cash from Operations Change in Account Payables Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Inventory Change in Receivables Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Divestments Dividends Paid - Common Exchange Rate Effect Free Cash Flow Gains from Investment Securities Net Cash Flow Net Income Other financing activities Sales of Property, Plant and Equipment

Daily Values

DMA 100 DMA 200 DMA 50 Dividend Yield EV to CFO EV to EBIT EV to EBITDA EV to FCF EV to Revenue Market Cap to FCF Market Capitalization Price Price to Book Price to Earnings Price to Sales

Growth Metrics

Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)Dividends Paid - Common (QoQ)Dividends Paid - Common Growth (1y)Dividends Paid - Common Growth (3y)Dividends Paid - Common Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)FCF Payout Ratio (QoQ)FCF Payout Ratio Growth (1y)FCF Payout Ratio Growth (3y)FCF Payout Ratio Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Interest Coverage Ratio Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Equity Growth (5y)Return on Invested Capital (QoQ)Return on Invested Capital Growth (1y)Return on Invested Capital Growth (3y)Return on Invested Capital Growth (5y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)Tax Rate Growth (1y)Tax Rate Growth (3y)Tax Rate Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)

Income Statement

Amortization - Intangibles Consolidated Net Income Cost of Revenue EBIT EBITDA EBT EPS (Basic)EPS (Weighted Average and Diluted)Equity Income Gross Profit Income from Continuing Operations Income from Non-Controlling Interests Income towards Parent Company Interest & Investment Income Interest Expenses Net Income towards Common Stockholders Non Operating Income Operating Expenses Operating Income Profit After Tax Research & Development Restructuring Costs Revenue Selling, General & Administrative Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions Tax Rate

Others

Accumulated Depreciation & Amortization Amortization - Goodwill EBIAT Leases Loans and Notes Receivables Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Pension (IS)Property, Plant & Equipment (Gross)Receivables Refunds Shares Repurchased Short-Term Debt issuances

Ratios

Asset Utilization Ratio Assets Average Debt Ratio Debt to Equity EBIT Margin EBITDA Margin EBT Margin Enterprise Value Equity Average Equity Ratio FCF Margin FCF Payout Ratio Gross Margin Interest Coverage Ratio Inventory Average Invested Capital Net Margin Operating Margin Return on Assets Return on Capital Employed Return on Equity Return on Invested Capital Return on Sales Times Interest Earned

Research Tools

Takeda Pharmaceutical (TAK) OPEX Segregation (2016 - 2024)

Peer Comparison

Historic Data

Research Tools

Takeda Pharmaceutical (TAK) OPEX Segregation (2016 - 2024)

Peer Comparison

Historic Data

Create an account

Sign In

Reset Password